KemPharm (KMPH) Reports In-Line Q3 EPS
Get Alerts KMPH Hot Sheet
Join SI Premium – FREE
KemPharm (NASDAQ: KMPH) reported Q3 EPS of ($0.19), in-line with the analyst estimate of ($0.19). Revenue for the quarter came in at $2.87 million versus the consensus estimate of $2.97 million.
For earnings history and earnings-related data on KemPharm (KMPH) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Midday movers: RH, Estee Lauder rise; Tesla falls
- Can-Fite BioPharma (CANF) Reports FY23 Results, Issues Clinical Update
- VNET Group (VNET) Tops Q4 EPS by 18c, provides guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!